Do you want to read an article? Please log in or register.
Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
BJU Int
McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA
doi: 10.1111/bju.70044
Genitourinary Cancer
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy
BJU Int
Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
doi: 10.1111/bju.16895
COMMENTED
Genitourinary Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group
doi: 10.1200/JCO-25-01324
Genitourinary Cancer
Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged ≤45: A Retrospective Matched Cohort Study
J Urol
St-Laurent MP, Din S, Moryousef J, Lajkosz K, Kwong JCC, Chan A, Kim J, Taborek A, Chadee A, Sadri I, Reznik G, Tin C, Fleshner NE, Kulkarni GS, Black PC, Kassouf W, Zlotta AR
doi: 10.1097/JU.0000000000005183
Genitourinary Cancer
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
J Urol
Prasad SM, Shishkov D, Mihaylov NV, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Burger B, Meads A, Schoenberg M
doi: 10.1097/JU.0000000000005041
Genitourinary Cancer
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer
BJU Int
Abou Chakra M, McElree IM, Mott SL, O'Donnell MA
doi: 10.1111/bju.70149
Genitourinary Cancer
Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin
J Urol
Bahlburg H, Maas M, Contreras-Sanz A, Othman D, St-Laurent MP, Nikkola J, Chai S, Phillips KG, Hamlington B, Lentz PS, Lumbres NP, Bicocca VT, Jalanko T, Levin TG, Lange D, Black PC
doi: 10.1097/JU.0000000000005130
COMMENTED
Genitourinary Cancer
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Bladder Cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Lerner SP, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora PM, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel RT, Templeton AJ, Vogl U, Wettstein MS, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser CD
doi: 10.1177/23523735251410823
Gynecologic Cancer
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP)
doi: 10.1001/jamaoncol.2026.1924